Highest-materiality recent filing
Alnylam Q1 net product revs $1.04B (+121%); GAAP EPS $1.51 vs -$0.14; reaffirms FY26 guidance
Global net product revenues $1,036M, up 121% YoY; total TTR revenues $910M (+153%).
Alnylam grants CEO Greenstreet performance-based PSUs tied to $500-$800 stock price by 2029
Target of 55,373 PSUs ($18.0M face value at $325.07 close on grant date).
Alnylam posts Q4 net product rev $995M (+121%); achieves full-year GAAP profitability
Q4 2025 net product revenue $995M (+121% YoY); full-year $2,987M (+81%); total revenue Q4 $1.1B.
Alnylam reports preliminary 2025 net product revs $2,987M (+81% YoY); guides 2026 revs $4.9B-$5.3B
Preliminary 2025 net product revenue $2,987M (81% growth vs 2024); TTR franchise $2,487M (103% growth).
Alnylam Q3 net product rev $851M (+103% YoY); raises 2025 guidance 10% to $2.95-3.05B
Total net product revenues $851M (+103% YoY); TTR franchise $724M (+135% YoY) led by AMVUTTRA ATTR-CM launch.
Issued $661.25M aggregate principal of 0.00% Convertible Senior Notes due 2028; initial conversion price $670.11/share (~40% premium).
Alnylam prices $575M zero-coupon convertible notes due 2028; repurchases $637.8M of 2027 notes
$575M principal of 0.00% convertible senior notes due 2028 priced; initial conversion price ~$670.11/share, 40% premium to VWAP.
Alnylam Q2 net product rev $672M (+64% YoY); TTR franchise $544M (+77%); raises FY guidance
Q2 net product revenues $672M, +64% YoY; TTR franchise $544M (+77%) driven by AMVUTTRA sales of $492M.
Alnylam promotes Pushkal Garg to Chief R&D Officer; merges R&D functions
Pushkal Garg appointed EVP, Chief Research and Development Officer to lead integrated R&D organization.
Alnylam Q1 product rev $469M (+28% YoY); AMVUTTRA approved for ATTR-CM; guides FY25 $2.05-2.25B
Q1 total revenues $594M, up 20% YoY; GAAP operating income $18M vs loss of $43M in Q1 2024.
Alnylam gets FDA approval for AMVUTTRA in ATTR-CM, first RNAi therapy for cardiomyopathy
FDA approved AMVUTTRA for ATTR-CM to reduce cardiovascular mortality, hospitalizations, and urgent heart failure visits.
Alnylam Q4 product rev $451M (+30%); FY rev $1.65B (+33%); vutrisiran sNDA PDUFA Mar 23
Q4 2024 global net product revenues $451M (+30% vs Q4 2023); full year $1,646M (+33%).
Q4 2024 net product revenues ~$451M; FY2024 ~$1,646M, representing 33% annual growth.
Alnylam Q3 product revenue $420M (+34%); GAAP EPS -$0.87, guidance reaffirmed
Global net product revenues $420M, up 34% YoY; TTR (ONPATTRO+AMVUTTRA) $309M, Rare (GIVLAARI+OXLUMO) $111M.
Alnylam Q2 net product rev $410M +34% YoY; HELIOS-B positive; guidance raised
Global net product revenue $410M, up 34% YoY; TTR business (ONPATTRO+AMVUTTRA) grew 37% YoY.
Alnylam Q1 net product rev $365M (+32% YoY); net loss narrows to $0.52/share
Net product revenue $365M, up 32% YoY; TTR franchise $264M (+29%), Rare $101M (+40%).
Q4 net product revenue $346M: ONPATTRO $79M, AMVUTTRA $175M, GIVLAARI $59M, OXLUMO $33M.
Alnylam prelim 2023 product rev $1.24B (+39% YoY); Q4 growth across all drugs
Full-year 2023 global net product revenues $1,241M, up 39% YoY (39% constant currency).
Alnylam Q3 2023 net product revenues $313M (+35% YoY); FDA CRL for ONPATTRO cardiomyopathy
Q3 net product revs $313M (+35% YoY); GAAP net income $147.8M ($1.15 diluted EPS) vs loss of $405.9M in Q3 2022.
FDA rejects Alnylam's patisiran sNDA for ATTR cardiomyopathy; company abandons U.S. expansion
FDA issued Complete Response Letter citing insufficient evidence of clinical meaningfulness for patisiran in cardiomyopathy of ATTR amyloidosis.
Alnylam Q2 net product revenues up 43% to $306M; Vaishnaw steps down as President
Net product rev $306M (+43% YoY); GAAP net loss $276M ($2.21/share), non-GAAP net loss $202M ($1.62/share).
Alnylam partners with Roche on zilebesiran; receives $310M upfront, up to $2.5B milestones
Upfront cash payment of $310 million; potential total deal value up to $2.8 billion including development, regulatory, and sales milestones.
FDA Advisory Committee (Cardiovascular and Renal Drugs) to review sNDA for patisiran in cardiomyopathy of ATTR amyloidosis on Sept 13, 2023.
Alnylam Q1 product rev $276M (+48% YoY); ALN-APP CNS data positive; FY guidance reaffirmed
Q1 net product revenue $276M (+48% YoY); AMVUTTRA $102M and ONPATTRO $102M drove TTR growth of 49%.
Alnylam Q4 2022 product revenue $262M (+35% YoY); guides 2023 revenue $1.2-1.285B
Q4 2022 net product revenue $262M; full year $894M (+35% YoY). GAAP net loss $1.13B for 2022 vs $853M in 2021.
Alnylam reports preliminary FY2022 net product revenue of $894M, up 35% YoY
ONPATTRO: Q4 $122M, FY $558M; AMVUTTRA: Q4 $69M, FY $94M; combined TTR revenue grew 37% YoY.
Q3 2022 GAAP net loss $405.9M ($3.32/sh) vs $204.5M ($1.72/sh) YoY; non-GAAP net loss $193.4M ($1.58/sh) vs $189.8M ($1.59/sh).
Alnylam closes $1.035B convertible note offering; repays $762M credit facility
Issued $1.035B aggregate principal of 1.00% Convertible Senior Notes due 2027 (initial $900M plus $135M additional).
Alnylam prices $900M convertible senior notes at 1.00% due 2027; conversion premium 35%
Principal $900M (greenshoe up to $135M); interest 1.00% semi-annual; maturity Sept 15, 2027.
Alnylam Q2 product revenue $214M (+33%); AMVUTTRA FDA approved; guidance reiterated
Q2 net product revenues $214M: ONPATTRO $153M, GIVLAARI $45M, OXLUMO $15M, up 33% YoY.
Alnylam gets FDA approval for AMVUTTRA (vutrisiran) for hATTR amyloidosis polyneuropathy
FDA approval based on HELIOS-A Phase 3: 17.0-point mean improvement in mNIS+7 vs placebo (p<0.0001); 50% of patients saw improvement.
Alnylam Q1 product revenue $187M, GAAP loss $240M; lowers 2022 guidance to $870-930M
Q1 total net product revenue $187M (+38% YoY); GAAP net loss $240M ($2.00 EPS), non-GAAP loss $180M ($1.49 EPS).
Alnylam's vutrisiran PDUFA delayed 3 months to July 14, 2022 on packaging facility issue
FDA extended review to July 14, 2022 due to amendment addressing inspection classification at third-party packaging/labeling facility.
Filed lawsuits in U.S. District Court for Delaware against Pfizer and Moderna.
Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.
the Committee approved (i) the appointment of Pushkal Garg, M.D., the Company’s current Chief Medical Officer, Executive Vice President, Development and Medical Affairs, to the position of Executive Vice President, Chief Research and Development Officer
On March 3, 2025, Phillip A. Sharp, Ph.D. informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of his retirement from the Board, effective as of May 8, 2025.
Indrani L. Franchini agreed that she would transition from her role as the Company’s Executive Vice President, Chief Legal Officer and Secretary, effective as of March 1, 2024
On January 12, 2024, Alnylam Pharmaceuticals, Inc. (the “Company”) and Indrani L. Franchini agreed that she would transition from her role as the Company’s Executive Vice President, Chief Legal Officer and Secretary, effective as of March 1, 2024
On September 26, 2023, Marsha H. Fanucci informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of her resignation from the Board effective as of September 29, 2023.
On July 31, 2023, the Company and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement (the “Letter Agreement”), whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023 (the “Transition Date”).
Effective as of March 7, 2023, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from twelve to thirteen and elected Peter N. Kellogg to fill the newly created vacancy.
Effective as of January 5, 2023, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from eleven to twelve and elected Dr. Carolyn R. Bertozzi to fill the newly created vacancy.
Effective as of August 22, 2022, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Dr. Elliott Sigal to fill the newly created vacancy.
On March 31, 2022, Steven M. Paul, M.D. informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of his resignation from the Board effective as of April 16, 2022.
On January 4, 2022, Alnylam Pharmaceuticals, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Akshay K. Vaishnaw, M.D., Ph.D., the Company’s current President, Research and Development, as President effective January 1, 2022.
Max materiality 0.90 · Median 0.70 · Most common event earnings